Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

about

Biomarkers in localized prostate cancer.What's new in screening in 2015?

P2860

Q38697114-124B092F-BECD-4767-947B-C6BF3B8224F6 Q38871819-E6922C14-33E5-4148-BDEA-27A81D710680

P2860

Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

Item

http://www.wikidata.org/entity/Q38546301

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

@en

type

Item

label

Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

@en

prefLabel

Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

@en

P1476

Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

@en

P2093

Ganesh Palapattu

http://www.w3.org/2001/XMLSchema#string

John Wei

http://www.w3.org/2001/XMLSchema#string

Todd Morgan

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Cancer statistics, 2014

Screening and prostate-cancer mortality in a randomized European study

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer.

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

P2888

s11934-015-0537-3

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11934-015-0537-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023773542

http://www.w3.org/2001/XMLSchema#string

P698

26169584

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

about

P2860

P2860

Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921